## EDITORIAL

1544  
Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype  
Jeong KY, Lee H

## OPINION REVIEW

1551  
New drugs for the treatment of metastatic colorectal cancer  
Cherri S, Libertini M, Zaniboni A

## REVIEW

1561  
Extracellular vesicles: General features and usefulness in diagnosis and therapeutic management of colorectal cancer  
Mammes A, Pasquier J, Mammes O, Conti M, Douard R, Loric S

1599  
Radiomics in hepatocellular carcinoma: A state-of-the-art review  
Yao S, Ye Z, Wei Y, Jiang HY, Song B

1616  
Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment  
Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A

1632  
Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer  

1648  
Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers  
Lv X, Xu G

## MINIREVIEWS

1668  
Novel perspective in pancreatic cancer therapy: Targeting ferroptosis pathway  

1680  
Liver tumors in children with chronic liver diseases  
Sintusek P, Phewplung T, Sampavat A, Poovorawan Y

1696  
Non-surgical treatment of hilar cholangiocarcinoma  
ORIGINAL ARTICLE

Basic Study
1709 Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT axis
Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ

1725 Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma

1741 Preventive and inhibitive effects of Yiwei Xiaoyu granules on the development and progression of spasmyloytic polypeptide-expressing metaplasia lesions
Chen WQ, Tian FL, Zhang JW, Yang XJ, Li YP

1755 Effects of dietary zinc deficiency on esophageal squamous cell proliferation and the mechanisms involved
Chen Y, Liu FX, Liu H

Case Control Study
1766 Genetic variation of TGF-BR2 as a protective genotype for the development of colorectal cancer in men
Stanilov N, Grigorova A, Velikova T, Stanilova SA

Clinical Trials Study
1781 Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer
Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK

SYSTEMATIC REVIEWS
1791 Colorectal cancer in Arab world: A systematic review

1799 Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A systematic review
Uhe I, Hagen ME, Ris F, Meyer J, Toso C, Douissard J

1813 Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review

META-ANALYSIS
1833 Anatomical vs nonanatomical liver resection for solitary hepatocellular carcinoma: A systematic review and meta-analysis
Liu H, Hu FJ, Li H, Lan T, Wu H
LETTER TO THE EDITOR

1847  Hepatocellular carcinoma biomarkers, an imminent need

Zamora-León SP
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Oncology, Wen-Wei Sung, MD, PhD, Associate Professor, Doctor, Surgeon, Department of Urology, School of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Taichung 40201, Taiwan. flutewayne@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
ISSN 1948-5204 (online)

LAUNCH DATE
February 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Rosa M Jimenez Rodriguez, Pashtoon M Kasi, Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
November 15, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2021 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
Colorectal cancer in Arab world: A systematic review


ORCID number: Nahed A Makhlouf 0000-0002-2949-4369; Muhammad Abdel-Gawad 0000-0002-0204-4715; Aya M Mahros 0000-0002-6849-4065; Sameh A Lashen 0000-0002-8599-1338; Mariam Zaghloul 0000-0002-4244-5396; Ahmed Eliwa 0000-0003-0818-3086; Eman E Elshemy 0000-0001-6040-9869; Zainab Ali-Eldin 0000-0001-5157-3149; Doaa Abdelwab 0000-0002-1150-1113; Fathiya El-Raey 0000-0001-5191-2278; Dalia Omran 0000-0002-5513-6955; Marwa Khalaf 0000-0002-8148-2966; Nancy Fanous 0000-0002-7552-9991; Ahmed Shawkat Abdelmohsen 0000-0002-7429-4529; Ahmed Abu-Elfath 0000-0003-3269-5284; Mohamed Abdelghani 0000-0003-1370-5336; Mahmoud Farouk 0000-0001-8924-0841; Mohamed Abdelaziz 0000-0003-1417-5429; Mohamed Alboraie 0000-0002-8409-9822.

Author contributions: Makhlouf NA designed the research; Khalaf M did the registration on PROSPERO; Abdel-Gawad M performed the literature search and the statistical analysis; Mahros AM, Lashen SA, Eliwa A, Elshemy EE, Ali-Eldin Z, Abdelwab D, El-Raey F, Omran D, Fanous N, Khalaf M, Abu-Elfath A, Abdelghani M, Farouk M, Abdelmohsen AS and Abdelaziz M performed title, abstract screening, full article screening and data extraction; Makhlouf NA and

Nahed A Makhlouf, Doaa Abdelwab, Ahmed Shawkat Abdelmohsen, Ahmed Abu-Elfath, Mohamed Abdelghani, Mahmoud Farouk, Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt

Muhammad Abdel-Gawad, Department of Hepatology, Gastroenterology, and Infectious Diseases, Al-Azhar University, Assiut 71631, Egypt

Aya M Mahros, Mariam Zaghloul, Department of Hepatology, Gastroenterology and Infectious Diseases, Kafrelsheikh University, Kafrelsheikh 33656, Egypt

Sameh A Lashen, Department of Internal Medicine, Alexandria University, Alexandria 21521, Egypt

Ahmed Eliwa, Mohamed Alboraie, Department of Internal Medicine, Al-Azhar University, Cairo 11884, Egypt

Eman E Elshemy, Department of Hepatogastroenterology and Infectious Diseases, Al-Azhar University, Cairo 11651, Egypt

Zainab Ali-Eldin, Department of Internal Medicine, Ain Shams University, Cairo 11646, Egypt

Fathiya El-Raey, Department of Hepatogastroenterology and Infectious diseases, Faculty of Medicine, Al-Azhar University, Damietta 34511, Cairo, Egypt

Dalia Omran, Department of Endemic Medicine, Cairo University, Cairo 12613, Egypt

Marwa Khalaf, Department of Tropical Medicine and Gastroenterology, Assiut Liver Center, Assiut 71511, Egypt

Nancy Fanous, Department of Gastroenterology, Hepatology and Endoscopy, Police Authority Hospital, Cairo 12654, Egypt

Mohamed Abdelaziz, Department of Clinical Oncology and Nuclear Medicine, Al-Azhar University, Cairo 11824, Egypt

Corresponding author: Nahed A Makhlouf, MD, Professor, Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut University Street, Assiut 71515, Egypt. nahedmak@yahoo.com
Colorectal cancer in Arab world.

Abstract

BACKGROUND
The incidence of colorectal cancer (CRC) is increasing among young individuals in the Arab world as well as in other regions of the world.

AIM
To explore the incidence and prevalence of CRC in the Arab world.

METHODS
The PubMed, Scopus, Web of Science, EBSCO and Wiley databases were searched to retrieve relevant articles irrespective of the language or the publication year. The search terms were “("colon OR rectum OR sigmoid OR rectal OR colonic OR colorectal") AND ("cancer OR malignancy OR malignant OR neoplasm") AND ("Jordan" OR "United Arab Emirates" OR "Bahrain" OR "Tunisia" OR "Algeria" OR "Djibouti" OR "Saudi Arabia" OR "Sudan" OR "Syria" OR "Somalia" OR "Iraq" OR "Oman" OR "Palestine" OR "Qatar" OR "Comoros" OR "Kuwait" OR "Lebanon" OR "Libya" OR "Egypt" OR "Morocco" OR "Mauritania" OR "Yemen")". Reviews, meta-analyses, and articles containing nonoriginal data were excluded. Retrieved articles were screened, and relevant data were extracted. Descriptive statistics were used for data analysis.

RESULTS
Nine studies were included. Five of the studies provided information regarding the prevalence of CRC. The prevalence of CRC was 0.72% in Saudi Arabia and 0.78% in the United Arab Emirate, while in Egypt, it ranged from 0.4% to 14%. Four studies showed information regarding the incidence. The annual incidence rate of CRC in Qatar was 7.5/100000/year. In Egypt, the crude incidence rate (CIR) in males was 3.1 for colon cancer and 1 for rectal cancer, while in females, it was 2.3 for colon cancer and 0.8 for rectal cancer. The age-standardized rate for CRC incidence in 2003 was 36.90 for males, 26.50 for females, and 30.49 for both sexes in Saudi Arabia. In 2016, the CIRs in Saudi Arabia were 3.6 and 2.1 in females for colon cancer and rectal cancer, respectively, while in males, it was 3.3 and 2.8 for colon cancer and rectal cancer, respectively. One study in Egypt revealed that 25% of CRC cases occurred among individuals younger than 40 years old.

CONCLUSION
There is a considerable prevalence of CRC in some Arab countries. More studies are needed to explore the incidence and prevalence of CRC in the rest of the Arab world.

Key Words: Colorectal cancer; Incidence; Prevalence; Arab world

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Colorectal cancer (CRC) represents the third most common cause of cancer globally. Although only a few studies have addressed the prevalence and incidence of CRC in the Arab world, this systematic review found that there is a considerable prevalence of CRC in Egypt, Saudi Arabia, Qatar and the United Arab Emirate. More studies are needed to explore the incidence and prevalence of CRC in the rest of the Arab world.

DOI: https://dx.doi.org/10.4251/wjgo.v13.i11.1791
INTRODUCTION

Colorectal cancer (CRC) is the third most common cancer (10.0%), and it is the second leading cause of cancer deaths worldwide (9.4%)[1].

In the past decade, an increase in the incidence of CRC has been observed worldwide. Additionally, there is increase in the prevalence of CRC in the younger population, and new cases are expected to increase among the younger population aged 20–49 years by 2030[2,3].

In particular, the prevalence of CRC is increasing among young individuals in the Middle East and other regions in the world[4,5]. These changes in the incidence and epidemiology of the disease presentation have also been observed in the Arab world[2]. The influence of Western lifestyles on the Arab population has led to an increase in the prevalence of CRC and affected younger populations[2].

To our knowledge, there has been no systematic review on CRC prevalence and/or incidence in the Arab World.

The primary aim of this review was to explore the prevalence and/or incidence of CRC in the Arab world by reviewing the available literature studies from Arab countries.

MATERIALS AND METHODS

Literature search

The PubMed, Scopus, Web of Science, EBSCO and Wiley databases were searched using the following search terms: “("colon OR rectum OR sigmoid OR rectal OR colonic OR colorectal") AND ("cancer OR malignancy OR malignant OR neoplasm") AND ("Jordan" OR "United Arab Emirates" OR "Bahrain" OR "Tunisia" OR "Algeria" OR "Djibouti" OR "Saudi Arabia" OR "Sudan" OR "Syria" OR "Somalia" OR "Iraq" OR "Oman" OR "Palestine" OR "Qatar" OR "Comoros" OR "Kuwait" OR "Lebanon" OR "Libya" OR "Egypt" OR "Morocco" OR "Mauritania" OR "Yemen")”, to retrieve relevant articles irrespective of the language or the publication year of the articles. For non-English articles, all relevant data were taken from the English abstract, and two reviewers translated the full text to English to retrieve all other data of interest.

Reviews, meta-analyses, and all other articles containing nonoriginal data were excluded from our review. All retrieved articles were screened and selected by three independent authors. Relevant data were extracted into a standardized data collection sheet by four independent authors. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart is shown in Figure 1. This systematic review was registered in the PROSPERO registry (CRD42021226703).

Statistical analysis

Descriptive statistics were used for data analysis.

RESULTS

At the time of this review, a total of nine studies containing information about the prevalence and/or incidence of CRC in the Arab world were included[6-14] (Table 1). Five studies provided information regarding the prevalence of CRC in Arab Worlds [one from Saudi Arabia[6], 3 from Egypt[9,11,12], and one from the United Arab Emirates (UAE)[13].

The prevalence of CRC was 0.72% in Saudi Arabia[6] and 0.78% in the UAE[13], while Egypt reported different prevalence rates of 0.4%[11], 9.4%[12] and 14%[9].

Among these studies, four showed information regarding the incidence of CRC in the Arab world[7,8,10,14]. In their retrospective analysis of Qatar’s area, Rasul et al[7] reported an average annual incidence rate of 7.5/100000/year. A retrospective study in Egypt (from 2008 to 2011) revealed that the crude rate in males was 3.1 for colon cancer and 1 for rectal cancer, while in females, it was 2.3 for colon cancer and 0.8 for rectal cancer[10].

The age-standardized rate for CRC incidence in 2003 was 36.90 for males, 26.50 for females, and 30.49 for both sexes in Saudi Arabia, as reported by Ibrahim et al[8].

However, another retrospective analysis of Saudi Arabia Ministry of Health Registry data including 13013 participants from general population was conducted in 2016; the crude incidence rates (CIRs) for colon and rectal cancer among females were 3.6 and
## Table 1 Summary of included studies

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Year</th>
<th>Country</th>
<th>Study type</th>
<th>Number of participants</th>
<th>Population</th>
<th>Age</th>
<th>Male</th>
<th>Female</th>
<th>Prevalence</th>
<th>Incidence</th>
<th>Diagnostic test</th>
<th>Period of assessment</th>
<th>Affected colon segment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salih et al [6]</td>
<td>2014</td>
<td>Saudi Arabia</td>
<td>Retrospective case-control study</td>
<td>1600</td>
<td>General</td>
<td>49 (32-62)</td>
<td>No data</td>
<td>0.72% (12/1600)</td>
<td>No</td>
<td>Colonscopy and biopsy</td>
<td>No data</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td>Rasul et al [7]</td>
<td>2001</td>
<td>Qatar</td>
<td>Retrospective analysis</td>
<td>45</td>
<td>CRC patients attended to Hamad General Hospital</td>
<td>Mean 57.1, Range 33-83</td>
<td>26</td>
<td>19</td>
<td>No data</td>
<td>24pts/year. Average annual incidence 7.5/100000/year</td>
<td>Biopsy</td>
<td>1994 to 1998</td>
<td>Descending 55.5% and rectum 24%</td>
</tr>
<tr>
<td>Ibrahim et al [8]</td>
<td>2008</td>
<td>Saudi Arabia</td>
<td>Retrospective</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>Age-standardized rate for incidence in 2003 is 36.90 for males, 26.50 for females, and 30.49 for both sexes</td>
<td>No data</td>
<td>1994 to 2003</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td>Gado et al [9]</td>
<td>2014</td>
<td>Egypt</td>
<td>Descriptive cross-sectional hospital-based study.</td>
<td>412</td>
<td>Colonoscopies for symptomatized patients</td>
<td>Mean 51, Range 16-80</td>
<td>No data</td>
<td>56% of patient</td>
<td>57 (14%) Peak frequencies were in the 5th and 7th. Decade, 25% of cancers occurred in patients aged less than 40 yr</td>
<td>No data</td>
<td>Colonscopy and biopsy</td>
<td>2000-2012</td>
<td>(53%) in the left colon (sigmoid colon, descending colon and splenic flexure) and (16%) in the rectum, (32%) in the proximal colon (cecum, ascending colon, hepatic flexure and transverse colon, synchronous tumors in (2%)</td>
</tr>
<tr>
<td>Ibrahim et al [10]</td>
<td>2014</td>
<td>Egypt</td>
<td>Retrospective</td>
<td>No data</td>
<td>Colonoscopies</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>Crude rate in males: 3.1 for colon and 1 for rectal cancer. While in females: 2.3 for colon cancer and 0.8 for rectal cancer</td>
<td>No data</td>
<td>2008 to 2011</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td>Elwassief et al [11]</td>
<td>2015</td>
<td>Egypt</td>
<td>Questionnaire</td>
<td>547</td>
<td>Relatives of CRC patients</td>
<td>49 ± 9</td>
<td>335</td>
<td>212</td>
<td>2 (0.4%)</td>
<td>No data</td>
<td>Colonscopy and biopsy</td>
<td>No data</td>
<td>Distal</td>
</tr>
<tr>
<td>Gado et al [12]</td>
<td>2016</td>
<td>Egypt</td>
<td>Retrospective</td>
<td>286</td>
<td>Colonoscopies, 96.5% of cases had symptoms</td>
<td>25.1 ± 22</td>
<td>153</td>
<td>133</td>
<td>27 (9.4%)</td>
<td>No data</td>
<td>Colonscopy and biopsy</td>
<td>2010-2014</td>
<td>No data</td>
</tr>
<tr>
<td>Fayadh et al [13]</td>
<td>2019</td>
<td>United Arab Emerate (UAE)</td>
<td>8 yr observational study</td>
<td>7540</td>
<td>Colonoscopies</td>
<td>Average age (53), 46% of cancers below age 50 and 14% below the age of 40 years</td>
<td>No data</td>
<td>No data</td>
<td>69 (0.78%)</td>
<td>No data</td>
<td>Colonscopy</td>
<td>2012-2019</td>
<td>No data</td>
</tr>
<tr>
<td>Almatroudi</td>
<td>2020</td>
<td>Saudi</td>
<td>Retrospective</td>
<td>13013</td>
<td>General</td>
<td>No data</td>
<td>7116</td>
<td>5897</td>
<td>No data</td>
<td>In 2016 CIR in females</td>
<td>No data</td>
<td>2006 to 2016</td>
<td>Rectum, colon</td>
</tr>
</tbody>
</table>
Regarding the age of CRC patients, there was predominance in the fourth or fifth decade of life\[^{6,7,11,13}\]. However, Gado et al\[^{9}\] in Egypt reported two peak frequencies in the fifth and seventh decades; 25% of CRC occurred in patients aged less than 40 years.

**DISCUSSION**

The updated CRC burden according to the latest GLOBOCAN 2020 estimates demonstrated that CRC ranks third among frequently newly diagnosed cancers, with almost 1.9 million new cases (10.0%), and second leading cause of death worldwide, with approximately 935000 deaths in 2020 (9.4%)\[^{1}\]. The incidence rates are 4-fold higher in countries with developed economies, mainly in European regions, Australia/New Zealand, and Northern America. Furthermore, the overall CRC trends are increasing for incidence and decreasing for mortality almost all over European countries, with some national and regional variability attributed to differing levels of healthcare expenditure and the resulting quality of screening, diagnosis, and treatment \[^{15,16}\]. Despite the rising trends of CRC, there is a paucity of data reporting the incidence and/or prevalence of CRC in Arabian countries. The retrieved 9 studies were mostly retrospective data analyses, with only four studies providing information regarding the incidence of CRC in the Arab world\[^{7,8,10,14}\].

CRC incidence has always been known as an indicator of higher levels of socioeconomic development and is dominant in countries undergoing major economic transition. This is well demonstrated in higher incidence in Europe, Australia and Northern America\[^{17-19}\]. Additionally, Almatroudi\[^{14}\], in his large epidemiological study of CRC in Saudi Arabia, showed that there was a markedly increasing incidence of CRC from 2006 to 2016. He attributed that increase to the large-scale screening program that increased the case detection rate and the change toward more unhealthy lifestyles with higher incidence in large cities, such as the regions of Riyadh, Makkah, and Eastern Province, where westernized lifestyles and flourishing industries are more evident. A hospital-based case-control study in Kuwait concluded that CRC risk is

<table>
<thead>
<tr>
<th>[14]</th>
<th>Arabia</th>
<th>analysis of Saudi MOH registry data</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(4157 colon cancer and 2959 rectal cancer)</td>
</tr>
</tbody>
</table>

MOH: Ministry of health; CIR: Crude incidence rate.
strongly attributed to higher body mass index, excessive red and processed meat consumption and decreased fruit/vegetable consumption[20].

The rising trend of CRC despite the screening programs adopted in many countries was disappointing. This was partly justified by the favorable outcomes of screening, and a decline in incidence within older age groups was not able to overcome the rising incidence of CRC in a younger population[21-23]. This was in accordance with Fayadh et al[13] in their single center experience of CRC screening in UAE from 2012 to 2019, which demonstrated increasing trends in CRC with an average age of 53 years. Of note, 46% of CRC cases were below the age of 50. Furthermore, another single center experience from Egypt reported that approximately 25% of CRC cases occurred in individuals younger than 40 years of age[9].

Limitations of our study
Our study has some limitations. There were few studies that met our inclusion criteria, and many Arab countries were not represented due to the lack of suitable studies for our review. There were not enough data to examine some questions of interest, such as regional differences in the prevalence, epidemiology and risk factors for CRC in Arab countries and the lack of programmed screening and/or surveillance strategies for CRC in most Arab countries.

CONCLUSION
In conclusion, there is a considerable prevalence of CRC in some Arab countries. More studies are needed to explore the incidence and prevalence of CRC in the rest of the Arab world.

Recommendations: Based on the available literature, it is recommended that multicenter prospective studies be conducted to assess the actual prevalence and incidence of CRC in different Arab countries and in different age groups. Proper
utilization of retrospective data emerging from currently running CRC screening programs in some countries and establishment of new screening programs in other countries will guide decisions in management and prevention strategies to contain the rising incidence of CRC in the Arab world. Proper awareness about CRC and early screening among the population represents the initial step to prevent morbidity and mortality resulting from CRC.

ARTICLE HIGHLIGHTS

Research background
Morbidity and mortality of colorectal cancer (CRC) is increasing globally. There is a particular concern about the rising incidence of CRC in young people in different parts of the world.

Research motivation
It is crucial for each country/region to know the actual prevalence, incidence, and predisposing factors for CRC to help in adequate planning for screening programs, preventive measures, and proper allocation of health care resources.

Research objectives
The main objective of this study was to explore and summarize the available evidence about prevalence and/or incidence of CRC in the Arab world.

Research methods
A systematic review of available literature was done to retrieve articles containing original data about CRC in the Arab world. Available data were extracted and summarized.

Research results
Nine studies including data about CRC in 5 Arab countries were found. Reported prevalence of CRC in Saudi Arabia was 0.72%, in United Arab Emirates was 0.78% and in Egypt ranged from 0.4%-14%. Qatar reported an average annual incidence rate of 7.5/100000/year. Egypt reported a crude rate of 3.1 in males and 2.3 in females. In Saudi Arabia, the crude incidence rate for CRC was 3.6 and 3.3 among females and males respectively. CRC tends to occur in the fourth or fifth decade of life, however, 25% of CRC patients were less than 40 years.

Research conclusions
Some Arab countries have a considerable prevalence of CRC. More data are expected to arise from the currently running CRC screening programs.

Research perspectives
Multicenter prospective trials and proper utilization of retrospective data are needed to assess the actual prevalence and incidence of CRC in different Arab countries.

REFERENCES

6 Salih MA, Murshid WR, Mohamed AG, Ignacio LC, de Jesus JE, Baabbad R, El Bushra HM. Risk
Makhlouf NA et al. Colorectal cancer in Arab world

factors for neural tube defects in Riyadh City, Saudi Arabia: Case-control study. *Sudan J Paediatr* 2014; 14: 49-60 [PMID: 27491405]


16 Pâun I, Constantin V, Soacea B, Bobic SJCeTV. The impact of environmental factors upon the incidence rate of colorectal cancer. *Ciência e Técnica Vitivinícola* 2015; 30: 11 [DOI: 10.24264/icams-2018.i.5]


18 Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. *Int J Cancer* 2016; 139: 2436-2446 [PMID: 27522007 DOI: 10.1002/jic.30582]


